Back to search

Article

Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms

2023-05-04

Abstract excerpt

<h4>Background: </h4> Immunohistochemical (IHC) PD-L1 expression is commonly employed as predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC). However, IHC evaluation methods are non-uniform and further studies are needed to optimize clinical utility. <h4>Methods: </h4> We compared the concordance, prognostic value and gene expression between PD-L1 IHC expression by SP142 immune...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
694151b1-79b8-58c9-9a5f-0e9b0635a9f9
DOI
10.21203/rs.3.rs-2841893/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithmsDOI 10.21203/rs.3.rs-2841893/v1
Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohortSemantic proximity
Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohortSemantic proximity
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancerSemantic proximity
Early triple negative breast cancers in a Singapore cohort exhibit high PIK3CA mutation rates associated with low PD-L1 expressionSemantic proximity
The Correlation of PD-L1 Expression in Metaplastic BreastCancers with Clinical-Pathological Features and PrognosisSemantic proximity
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast CancerSemantic proximity
Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancerSemantic proximity
A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer.Semantic proximity
Construction and validation of a gene expression classifier to predict immunotherapy response in primary triple-negative breast cancerSemantic proximity
Early Triple-Negative Breast Cancers in a Singapore Cohort Exhibit High PIK3CA Mutation Rates Associated With Low PD-L1 Expression.Semantic proximity
Expression of the Prostate Specific Membrane Antigen (PSMA) and Programmed Death-Ligand 1 (PD-L1) on Disseminated Tumor Cells from Early Triple Negative Breast Cancer Patients and their Clinical ImpactSemantic proximity
Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast CancerSemantic proximity
Select a neighboring publication to make it the new centre.